BTC 
ETH 
BNB 
XRP 
SOL 
TRX Nasdaq approves listing of Canary's staked Injective ETF
The Defiant reports that Nasdaq has approved the listing of Canary's staked Injective ETF. The proposed INJC fund would stake at least 90% of its INJ holdings and charge a 1.10% annual sponsor fee.
Why “Unverified”
- Reported by The Defiant alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 52/100. How labels work
What the sources claim
-
Nasdaq approved the listing of Canary's staked Injective ETF.
“Nasdaq Approves Listing of Canary’s Staked Injective ETF”
The Defiant -
The proposed INJC fund would stake at least 90% of its INJ holdings.
“The proposed INJC fund would stake at least 90% of its INJ holdings”
The Defiant -
The fund would charge a 1.10% annual sponsor fee.
“charge a 1.10% annual sponsor fee”
The Defiant
Sources
More in ETFs & Funds
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-04 20:40 UTC. Labels are computed from the sources, not by the model.